Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Investigating visual and anatomical outcomes of patients treated with ranibizumab and aflibercept for wet macular degeneration in the United Kingdom over a 3 year period

Michael Grinton; Michael McKenna; Sreekumari Pushpoth; Philip Severn

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):821. doi:

ARVO Annual Meeting Abstract June 2017

TWO-YEAR DATA COMPAIRING THE EFFICACY OF AFLIBERCEPT IN WET AGE-RELATED MACULAR DEGENERATION IN TREATMENT NAÏVE AND SWITCHOVER PATIENTS.

Michael McKenna; Javid Suleman; Darren S J Ting; Sreekumari Pushpoth; Philip Severn

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):422. doi:

ARVO Annual Meeting Abstract June 2017

Aflibercept 2mg (0.05mL) for the treatment of visual impairment due to macular oedema secondary to Central Retinal Vein Occlusion; does it really help?

MARCO Makram ISAC; Sridhar Manvikar; Philip Severn; Sreekumari Pushpoth

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1561. doi:

ARVO Annual Meeting Abstract September 2016

Efficacy of aflibercept in wet age-related macular degeneration non-responsive to ranibizumab

Darren Shu Jeng Ting; Javid Suleman; Philip S Severn; Sreekumari Pushpoth

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3348. doi:

ARVO Annual Meeting Abstract June 2015

Real-world data on intravitreal Aflibercept (Eylea) injection in patients with wet age-related macular degeneration

javid suleman; Darren Ting; Philip Stephen Severn; Sreekumari Pushpoth

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4610. doi:

Advertisement